CL2021003561A1 - Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal - Google Patents
Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatalInfo
- Publication number
- CL2021003561A1 CL2021003561A1 CL2021003561A CL2021003561A CL2021003561A1 CL 2021003561 A1 CL2021003561 A1 CL 2021003561A1 CL 2021003561 A CL2021003561 A CL 2021003561A CL 2021003561 A CL2021003561 A CL 2021003561A CL 2021003561 A1 CL2021003561 A1 CL 2021003561A1
- Authority
- CL
- Chile
- Prior art keywords
- neonatal
- amino acid
- receptor
- antibodies
- igg
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1072—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/534—Production of labelled immunochemicals with radioactive label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
- A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Optics & Photonics (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
Abstract
La invención se refiere a anticuerpos anti-CAIX que comprenden una región constante de cadena pesada que comprende una o más sustituciones de aminoácidos en comparación con una IgG de tipo natural, en donde la una o más sustituciones de aminoácidos reducen la afinidad del anticuerpo por el receptor de Fc neonatal (FcRn), reduciendo de ese modo la semivida sérica del anticuerpo modificado en comparación con un anticuerpo de tipo natural de clase IgG. La una o más modificaciones de aminoácidos que tienen el efecto de reducir la unión a FcRn se seleccionan de las posiciones His310, His433, His435, His436, Ile253. Los anticuerpos de la presente invención son particularmente idóneos para su uso en radioinmunoterapia.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2019902343A AU2019902343A0 (en) | 2019-07-02 | Antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2021003561A1 true CL2021003561A1 (es) | 2022-11-18 |
Family
ID=74100150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2021003561A CL2021003561A1 (es) | 2019-07-02 | 2021-12-29 | Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220331457A1 (es) |
EP (1) | EP3994176A4 (es) |
JP (1) | JP2022540384A (es) |
KR (1) | KR20220057516A (es) |
CN (1) | CN114502596A (es) |
AU (1) | AU2020299024A1 (es) |
BR (1) | BR112021026651A2 (es) |
CA (1) | CA3141457A1 (es) |
CL (1) | CL2021003561A1 (es) |
IL (1) | IL289524A (es) |
MA (1) | MA56467A (es) |
MX (1) | MX2021015670A (es) |
WO (1) | WO2021000017A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3229588A1 (en) * | 2021-09-01 | 2023-03-09 | Telix Pharmaceuticals (Innovations) Pty Ltd | Aggregate separation method |
WO2023235933A1 (en) * | 2022-06-09 | 2023-12-14 | Telix Pharmaceuticals (Innovations) Pty Ltd | Combination therapy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4263485B2 (ja) * | 2001-02-07 | 2009-05-13 | ヴィレックス アクチェンゲゼルシャフト | ハイブリドーマ細胞系g250およびモノクローナル抗体を製造するためのその使用 |
US20090162382A1 (en) * | 2002-03-01 | 2009-06-25 | Bernett Matthew J | Optimized ca9 antibodies and methods of using the same |
US8802820B2 (en) * | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
WO2007065027A2 (en) * | 2005-12-02 | 2007-06-07 | Dana Farber Cancer Institute | Carbonic anhydrase ix (g250) antibodies and methods of use thereof |
WO2008091798A2 (en) * | 2007-01-22 | 2008-07-31 | Xencor, Inc. | Optimized ca9 antibodies and methods of using the same |
CN102775500A (zh) * | 2012-08-03 | 2012-11-14 | 郑骏年 | 嵌合抗原受体iRGD-scFv(G250)-CD8-CD28-CD137-CD3ζ及其用途 |
EP3327034A1 (en) * | 2013-04-29 | 2018-05-30 | F. Hoffmann-La Roche AG | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
MX365787B (es) * | 2013-04-29 | 2019-06-14 | Hoffmann La Roche | Anticuerpos modificados de unión a receptor de fc neonatal (fcrn) humano y uso de los mismos. |
EP3835318A1 (en) * | 2014-01-15 | 2021-06-16 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and maintained protein a-binding properties |
BR112016014969A2 (pt) * | 2014-01-15 | 2018-01-23 | Hoffmann La Roche | polipeptídeo, formulação farmacêutica e uso de um polipeptídeo |
CN108699153B (zh) * | 2016-02-25 | 2022-09-23 | 细胞医学瑞士公司 | Pd-l1的结合成员 |
EP3502139A1 (en) * | 2017-12-19 | 2019-06-26 | Philogen S.p.A. | Antibodies to tumour antigens |
-
2020
- 2020-07-02 JP JP2021578267A patent/JP2022540384A/ja active Pending
- 2020-07-02 AU AU2020299024A patent/AU2020299024A1/en active Pending
- 2020-07-02 WO PCT/AU2020/050689 patent/WO2021000017A1/en active Application Filing
- 2020-07-02 US US17/622,341 patent/US20220331457A1/en active Pending
- 2020-07-02 CA CA3141457A patent/CA3141457A1/en active Pending
- 2020-07-02 BR BR112021026651A patent/BR112021026651A2/pt unknown
- 2020-07-02 MX MX2021015670A patent/MX2021015670A/es unknown
- 2020-07-02 MA MA056467A patent/MA56467A/fr unknown
- 2020-07-02 EP EP20834781.5A patent/EP3994176A4/en active Pending
- 2020-07-02 CN CN202080054196.6A patent/CN114502596A/zh active Pending
- 2020-07-02 KR KR1020227002842A patent/KR20220057516A/ko unknown
-
2021
- 2021-12-29 CL CL2021003561A patent/CL2021003561A1/es unknown
- 2021-12-30 IL IL289524A patent/IL289524A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2021000017A1 (en) | 2021-01-07 |
BR112021026651A2 (pt) | 2022-03-03 |
MA56467A (fr) | 2022-05-11 |
EP3994176A4 (en) | 2023-09-20 |
JP2022540384A (ja) | 2022-09-15 |
CA3141457A1 (en) | 2021-01-07 |
EP3994176A1 (en) | 2022-05-11 |
CN114502596A (zh) | 2022-05-13 |
AU2020299024A1 (en) | 2022-01-20 |
MX2021015670A (es) | 2022-04-18 |
IL289524A (en) | 2022-03-01 |
US20220331457A1 (en) | 2022-10-20 |
KR20220057516A (ko) | 2022-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2021003561A1 (es) | Anticuerpos contra caix con afinidad reducida por el receptor de fc neonatal | |
AR106189A1 (es) | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO | |
EA202190542A1 (ru) | Сконструированные биспецифические белки | |
BR112018067458A2 (pt) | anticorpos para tigit | |
EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201891582A1 (ru) | Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки | |
MX2020004129A (es) | Anticuerpos anti-cd38 y metodos de uso. | |
CY1120951T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
CL2017001866A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
CO2018010538A2 (es) | Anticuerpos específicos del receptor de poliovirus humano (rvp) | |
BR112018013677A2 (pt) | proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas | |
CY1114350T1 (el) | Δεσμευτικοι παραγοντες σκληροστινης | |
CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
CL2019003095A1 (es) | Anticuerpos anti-cd33 y métodos para utilizarlos. | |
UY36942A (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
CY1118420T1 (el) | Αντι-ιδιοτυπικο αντισωμα εναντι ενος αντισωματος εναντι του βητα αμυλοειδους πεπτιδιου | |
EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
EA201992278A1 (ru) | Способы и композиции для снижения иммуногенности | |
NI201800113A (es) | Anticuerpos anti-basigin humanizados y uso de los mismos. | |
BR112019008345A2 (pt) | anticorpos monoclonais ligados à isoforma transmembrana cd160 | |
AR073140A1 (es) | Anticuerpos anti-il-23r disenados | |
EA202092508A1 (ru) | Составы на основе антител к pd-l1 человека | |
EA202191231A1 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ЭНДОКРИННОЙ ОФТАЛЬМОПАТИИ С ПРИМЕНЕНИЕМ АНТИ-FcRn АНТИТЕЛ | |
BR112021026663A2 (pt) | Anticorpos para ligação a psma com afinidade reduzida para o receptor fc neonatal |